

Gerard Sanacora

Professor

Yale University

COI Disclosures

In the past 24 months Dr. Sanacora has received grants/research contracts from Johnson & Johnson/Janssen, Michael J Foxx Foundation, Merck, National Institutes of Health, and Patient Centered Outcomes Research Institute. He also served as consultant to Abbvie, Actinogen Medical, Alto Neuroscience, Atai, Allumis, Axsome Therapeutics, Biogen, Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Clexio, Denovo Biopharma, Douglas Pharmaceuticals, EMA Wellness, Embark, Freedom Biosciences, GH Research, Gilgamesh, Holmusk, Janssen, Lilly, Merck, , Neumora, Neurocrine, Newleos, Novartis, Relmada Therapeutics, Seaport Pharmaceuticals, Supernus, Tetricus, and Transcend Therapeutics. He also holds equity in Biohaven Pharmaceuticals, Freedom Biosciences, Gilead, Oui Therapeutics, Relmada, and Tetricus. He is a co-inventor on US patents (#8,778,979), (#11554117), (#10052318) (#11793794) and (#12090145). Yale University has a financial relationship with Janssen Pharmaceuticals and may receive financial benefits from this relationship. Dr. Sanacora receives no benefit from this agreement and the University has put multiple measures in place to mitigate this institutional conflict of interest. Questions about the details of these measures should be directed to Yale University's Conflict of Interest office.